Thioredoxin-1 mediates hypoxia-induced pulmonary artery smooth muscle cell proliferation

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 305, Issue 5, 2013, Pages

  Chen, Bernadette ^a,b   Nelin, Viktoria E ^a   Locy, Morgan L ^a   Jin, Yi ^a   Tipple, Trent E ^a,b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Hypoxia inducible factor; Phosphatidylinositol 3 kinase; Pulmonary hypertension; Serine threonine kinase

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; THIOREDOXIN 1; THIOREDOXIN REDUCTASE 1; THIOREDOXIN REDUCTASE 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HYPOXIA; LUNG HOMOGENATE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY ARTERY; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

HYPOXIA-INDUCIBLE FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PULMONARY HYPERTENSION; SERINE/THREONINE KINASE;

ANIMALS; ANOXIA; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; ENZYME INHIBITORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PULMONARY ARTERY; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THIOREDOXIN REDUCTASE 1; THIOREDOXINS; TRANSCRIPTION, GENETIC;

EID: 84883402103     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00432.2012     Document Type: Article

References (47)

1. Arner ES. Focus on mammalian thioredoxin reductases-important selenoproteins with versatile functions. Biochim Biophys Acta 1790: 495-526, 2009.
2. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102-6109, 2000.
3. Arner ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol 16: 420-426, 2006.
4. Cenas N, Prast S, Nivinskas H, Sarlauskas J, Arner ES. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. J Biol Chem 281: 5593-5603, 2006.
5. Chen B, Calvert AE, Cui H, Nelin LD. Hypoxia promotes human pulmonary artery smooth muscle cell proliferation through induction of arginase. Am J Physiol Lung Cell Mol Physiol 297: L1151-L1159, 2009.
6. Chen B, Calvert AE, Meng X, Nelin LD. Pharmacologic agents elevating cAMP prevent arginase II expression and proliferation of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 47: 218-226, 2012.
7. Chicoine LG, Paffett ML, Girton MR, Metropoulus MJ, Joshi MS, Bauer JA, Nelin LD, Resta TC, Walker BR. Maturational changes in the regulation of pulmonary vascular tone by nitric oxide in neonatal rats. Am J Physiol Lung Cell Mol Physiol 293: L1261-L1270, 2007.
8. Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW, Brielmeier M. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 24: 9414-9423, 2004.
9. Ebrahimian T, Touyz RM. Thioredoxin in vascular biology: role in hypertension. Antioxid Redox Signal 10: 1127-1136, 2008.
10. el-Hazmi MA, Warsy AS. Glutathione reductase deficiency in association with sickle cell and thalassaemia genes in Saudi populations. Hum Hered 35: 326-332, 1985.
11. el-Hazmi MA, Warsy AS. Glutathione reductase in the south-western province of Saudi Arabia-genetic variation vs. acquired deficiency. Haematologia (Budap) 22: 37-42, 1989.
12. el-Hazmi MA, Warsy AS. Riboflavin status in Saudi Arabia-a comparative study in different regions. Trop Geogr Med 41: 22-25, 1989.
13. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18: 1905-1914, 1999.
14. Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, Taraseviciene-Stewart L, Sung Y, Kraskauskas D, Farkas D, Conrad DH, Nicolls MR, Voelkel NF. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol 302: L977-L991, 2012.
15. Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 396: 120-124, 2010.
16. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S, 2004.
17. Imaoka H, Hoshino T, Takei S, Sakazaki Y, Kinoshita T, Okamoto M, Kawayama T, Yodoi J, Kato S, Iwanaga T, Aizawa H. Effects of thioredoxin on established airway remodeling in a chronic antigen exposure asthma model. Biochem Biophys Res Commun 360: 525-530, 2007.
18. 1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol 296: L489-L499, 2009.
19. 1 and IGFBP-3. Am J Physiol Lung Cell Mol Physiol 296: L489-L499, 2009.
20. Jakupoglu C, Przemeck GK, Schneider M, Moreno SG, Mayr N, Hatzopoulos AK, de Angelis MH, Wurst W, Bornkamm GW, Brielmeier M, Conrad M. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol Cell Biol 25: 1980-1988, 2005.
21. Kim WJ, Cho H, Lee SW, Kim YJ, Kim KW. Antisense-thioredoxin inhibits angiogenesis via pVHL-mediated hypoxia-inducible factor-1alpha degradation. Int J Oncol 26: 1049-1052, 2005.
22. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 277: 20336-20342, 2002.
23. Locy ML, Rogers LK, Prigge JR, Schmidt EE, Arner ES, Tipple TE. Thioredoxin reductase inhibition elicits Nrf2-mediated responses in Clara cells: implications for oxidant-induced lung injury. Antioxid Redox Signal 17: 1407-1416, 2012.
24. Luo C, Yi B, Bai L, Xia Y, Wang G, Qian G, Feng H. Suppression of Akt1 phosphorylation by adenoviral transfer of the PTEN gene inhibits hypoxia-induced proliferation of rat pulmonary arterial smooth muscle cells. Biochem Biophys Res Commun 397: 486-492, 2010.
25. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274, 2007.
26. Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J, Taketo MM. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 178: 179-185, 1996.
27. Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys 429: 123-133, 2004.
28. Mukherjee A, Martin SG. The thioredoxin system: a key target in tumour and endothelial cells. Br J Radiol 81: S57-S68, 2008.
29. Nonn L, Williams RR, Erickson RP, Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol Cell Biol 23: 916-922, 2003.
30. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 30: 421-455, 2001.
31. Prigge JR, Eriksson S, Iverson SV, Meade TA, Capecchi MR, Arner ES, Schmidt EE. Hepatocyte DNA replication in growing liver requires either glutathione or a single allele of txnrd1. Free Radic Biol Med 52: 803-810, 2012.
32. Rengby O, Cheng Q, Vahter M, Jornvall H, Arner ES. Highly active dimeric and low-activity tetrameric forms of selenium-containing rat thioredoxin reductase 1. Free Radic Biol Med 46: 893-904, 2009.
33. Rubinstein I, Langevitz P, Pras M. Aurothioglucose overdosage in five patients with rheumatoid arthritis. Clin Rheumatol 6: 583-587, 1987.
34. Sanders KA, Hoidal JR. The NOX on pulmonary hypertension. Circ Res 101: 224-226, 2007.
35. Scarbrough PM, Mapuskar KA, Mattson DM, Gius D, Watson WH, Spitz DR. Simultaneous inhibition of glutathione-and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress. Free Radic Biol Med 52: 436-443, 2012.
36. Schulze PC, De Keulenaer GW, Yoshioka J, Kassik KA, Lee RT. Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin. Circ Res 91: 689-695, 2002.
37. Schumacker PT. Hypoxia-inducible factor-1 (HIF-1). Crit Care Med 33: S423-S425, 2005.
38. Semenza GL. Oxygen sensing, homeostasis, disease. N Engl J Med 365: 537-547, 2011.
39. Shimoda LA, Manalo DJ, Sham JS, Semenza GL, Sylvester JT. Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am J Physiol Lung Cell Mol Physiol 281: L202-L208, 2001.
40. Shimoda LA, Semenza GL. HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med 183: 152-156, 2011.
41. Song S, Kang SW, Choi C. Trichostatin A enhances proliferation and migration of vascular smooth muscle cells by downregulating thioredoxin 1. Cardiovasc Res 85: 241-249, 2010.
42. Tipple TE, Welty SE, Rogers LK, Hansen TN, Choi YE, Kehrer JP, Smith CV. Thioredoxin-related mechanisms in hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 37: 405-413, 2007.
43. Toby IT, Chicoine LG, Cui H, Chen B, Nelin LD. Hypoxia-induced proliferation of human pulmonary microvascular endothelial cells depends on epidermal growth factor receptor tyrosine kinase activation. Am J Physiol Lung Cell Mol Physiol 298: L600-L606, 2010.
44. Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, Nikaido T. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274: 35809-35815, 1999.
45. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62: 5089-5095, 2002.
46. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2: 235-243, 2003.
47. Xu S, He Y, Vokurkova M, Touyz RM. Endothelial cells negatively modulate reactive oxygen species generation in vascular smooth muscle cells: role of thioredoxin. Hypertension 54: 427-433, 2009.